Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06354660 · ClinicalTrials.gov registry record · Phase 3
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
A Phase 3 study of Diabetes Type 2, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 537
- Enrollment target
- 20
- Study locations
NCT06354660: Completed Phase 3 study of Diabetes Type 2, sponsored by Eli Lilly and Company.
NCT06354660 is a Phase 3 study of Diabetes Type 2 that has completed, run by Eli Lilly and Company. The registered enrollment target is 537 participants, below the 645-participant average among 24 other Diabetes Type 2 trials with a reported enrollment target (17% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06354660, a Phase 3 study of Diabetes Type 2, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 537 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Retatrutide
Study Locations (20)
Florida
- Northeast Research Institute (NERI) - Fleming Island
- New Horizon Research Center - Miami
- Ezy Medical Research - Miami
- Clinical Research of Central Florida - Winter Haven
Arizona
- Scottsdale Clinical Trials - Scottsdale
- Tucson Clinical Research Institute - Tucson
California
- San Fernando Valley Health Institute - Canoga Park
- Ark Clinical Research - Long Beach
Pennsylvania
- Clinical Research of Philadelphia - Philadelphia
- Preferred Primary Care Physicians - Uniontown
Georgia
- Trinity Research Centers - Marietta
Kansas
- Cotton O'Neil Clinical Research Center - Topeka
Massachusetts
- NECCR PrimaCare Research - Fall River
Missouri
- Clinical Research Professionals - Chesterfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 537 participants |
| Start Date | 2024-04-10 |
| Est. Completion | 2026-02-20 |
| Phase | Phase 3 |
What the finished NCT06354660 record still lists
NCT06354660 is an interventional study that assigns participants to a tested intervention. The registered 537 participants enrollment target is mid-sized for trials with a published cap, below the 645-participant average among 24 other Diabetes Type 2 trials with a reported enrollment target (17% lower).
The record links to 1 condition, with Diabetes Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06354660 names 20 study sites across 14 states, led by Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06354660 about?
NCT06354660 is a clinical study titled "Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)". The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.
What is the current status of trial NCT06354660?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 537 participants. The study started on 2024-04-10. Estimated completion is 2026-02-20.
What conditions does trial NCT06354660 study?
This clinical trial studies the following conditions: Diabetes Type 2.
What interventions are being tested in trial NCT06354660?
The interventions under investigation include: Placebo (DRUG), Retatrutide (DRUG).
Who is sponsoring clinical trial NCT06354660?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06354660 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06354660's enrollment target sits among peer trials
537 4th of 24 higher than 21 of 24 other Diabetes Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
-
Lifestyle Interventions for Expectant Mothers (LIFE-Moms Phoenix) - Phoenix
COMPLETED · Phase 3
-
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
COMPLETED · Phase 3
-
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
RECRUITING · NA
-
Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age
RECRUITING · NA
-
Medically Intensive Nutrition Therapy Program for Obesity and Diabetes in a Low-income Population
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05880004 · 537 participants · NA
Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness
- NCT03772028 · 538 participants · Phase 3
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- NCT06538038 · 538 participants
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI